Close Menu
  • Home
  • AI
  • Art & Style
  • Economy
  • Entertainment
  • International
  • Market
  • Opinion
  • Politics
  • Sports
  • Trump
  • US
  • World
What's Hot

CEOs want to be social media influencers. Not everyone is on board.

December 21, 2025

Xbox is losing the console war against PlayStation and Switch

December 21, 2025

With Tyson Fury fight looming, Anthony Joshua explains why he needed to take a year off from boxing before his fight with Jake Paul | Boxing News

December 21, 2025
Facebook X (Twitter) Instagram
WhistleBuzz – Smart News on AI, Business, Politics & Global Trends
Facebook X (Twitter) Instagram
  • Home
  • AI
  • Art & Style
  • Economy
  • Entertainment
  • International
  • Market
  • Opinion
  • Politics
  • Sports
  • Trump
  • US
  • World
WhistleBuzz – Smart News on AI, Business, Politics & Global Trends
Home » Stocks with the biggest moves at midday: ORCL, BBWI, GAP
World

Stocks with the biggest moves at midday: ORCL, BBWI, GAP

Editor-In-ChiefBy Editor-In-ChiefNovember 21, 2025No Comments3 Mins Read
Share Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email Copy Link
Follow Us
Google News Flipboard
Share
Facebook Twitter LinkedIn Pinterest Email


Check out the companies that made the biggest moves midday: Oracle — AI stocks fell 4% as investors remained concerned about AI-related valuations. These declines compounded weekly losses for Oracle and Nvidia. Bath & Body Works — The retailer fell 5%, joining a 24.8% plunge from Thursday, as analysts around Wall Street downgraded the stock. Morgan Stanley and Goldman Sachs were among the companies that downgraded Bath & Body Works a day after the company reported weaker-than-expected third-quarter results. QuidelOrtho — The diagnostic products maker rose 11% after CEO Brian Blazer disclosed a purchase of 23,500 shares. AZENTA — Shares rose more than 10% after the laboratory equipment company reported fourth-quarter earnings that beat analysts’ expectations. The company reported earnings per share, excluding certain items, of 21 cents on revenue of $159.2 million. Analysts polled by FactSet had expected profit of 19 cents on revenue of $156.2 million. Enviri — The waste management company rose nearly 29% after it agreed to sell its hazardous and non-hazardous waste division, Clean Energy, to rival Veolia for $3.04 billion. Enviri will also spin off its Harsco Environmental and Rail divisions as New Enviri. The deal is expected to close in mid-2026. Bitcoin stocks — Stocks tied to the world’s oldest cryptocurrency were in the red as Bitcoin plummeted to nearly $80,000 as investors fled risky assets. Digital asset mining companies American Bitcoin and Riot Platforms fell 8% and 2% in deference. Bitcoin Financial Strategy fell 3%. Galaxy Digital fell 5%. Elastic — The data analytics company fell 14% after reporting second-quarter results that showed cloud growth slowed. Elastic’s adjusted earnings and revenue exceeded Wall Street expectations. Veeva Systems — Veeva Systems fell 11% after the cloud solutions provider said it expects fewer top biopharmaceutical companies to choose its Vault CRM. Veeva reported third-quarter earnings of $2.04 per share, excluding one-time items, and revenue of $811.2 million. That compared to analysts’ consensus estimates of $1.95 and revenue of $792.8 million. Gap — The apparel retailer saw same-store sales surge more than 8% in the latest quarter, beating expectations with a 5% increase in same-store sales thanks to its viral “Better in Denim” campaign with Katseye. Excluding the pandemic, same-store sales growth was the largest since the holiday quarter of fiscal 2017. Ross Stores — The retailer reported better-than-expected sales of $5.6 billion compared to the analyst consensus estimate of $5.42 billion, pushing the stock up 4%. Ross also raised his earnings outlook for the fourth quarter, saying, “We expect tariff-related costs to be negligible.” Anaptis Bio — The biotech company fell 2% after drugmaker Tesaro said it would sue Anaptis Bio for allegedly violating a licensing agreement for its oncology drug Gemperi. —CNBC’s Michelle Fox Theobald and Yun Li contributed reporting.



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Editor-In-Chief
  • Website

Related Posts

CEOs want to be social media influencers. Not everyone is on board.

December 21, 2025

I stayed in a sleeping pod in London.

December 20, 2025

How Build-A-Bear went from penny stock to retail winner

December 20, 2025
Add A Comment

Comments are closed.

News

‘Slap in the face’: Epstein victims condemn release of heavily edited files | Politics News

By Editor-In-ChiefDecember 20, 2025

Victims of Jeffrey Epstein are criticizing the US government after it released partial documents in…

US and Russian officials meet in Miami for talks on Ukraine war | Russia-Ukraine War News

December 20, 2025

Me Too Movement in the Age of Trump and Epstein | Women’s Rights

December 20, 2025
Top Trending

New York Governor Kathy Hochul signs RAISE Act regulating AI safety

By Editor-In-ChiefDecember 20, 2025

Governor Kathy Hochul signed the RAISE Act, making New York the second…

Resolve AI, a startup led by former Splunk executives, reaches $1 billion Series A valuation

By Editor-In-ChiefDecember 19, 2025

Resolve AI, a startup developing Autonomous Site Reliability Engineer (SRE), a tool…

Yann LeCun approves new ‘world model’ startup, reportedly seeking valuation of more than $5 billion

By Editor-In-ChiefDecember 19, 2025

Renowned AI scientist Yann LeCun admitted Thursday that he has launched a…

Subscribe to News

Subscribe to our newsletter and never miss our latest news

Welcome to WhistleBuzz.com (“we,” “our,” or “us”). Your privacy is important to us. This Privacy Policy explains how we collect, use, disclose, and safeguard your information when you visit our website https://whistlebuzz.com/ (the “Site”). Please read this policy carefully to understand our views and practices regarding your personal data and how we will treat it.

Facebook X (Twitter) Instagram Pinterest YouTube

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Facebook X (Twitter) Instagram Pinterest
  • Home
  • Advertise With Us
  • Contact US
  • DMCA Policy
  • Privacy Policy
  • Terms & Conditions
  • About US
© 2025 whistlebuzz. Designed by whistlebuzz.

Type above and press Enter to search. Press Esc to cancel.